Wall Street analysts expect that Arcadia Biosciences Inc (NASDAQ:RKDA) will post earnings per share of ($0.65) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Arcadia Biosciences’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.68). Arcadia Biosciences posted earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 364.3%. The company is scheduled to issue its next earnings report on Wednesday, March 25th.
According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($3.74) per share for the current financial year, with EPS estimates ranging from ($4.33) to ($3.15). For the next financial year, analysts anticipate that the company will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.54) to ($1.66). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.27). Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%. The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.31 million.
A number of research firms have recently commented on RKDA. ValuEngine lowered shares of Arcadia Biosciences from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 27th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of Arcadia Biosciences in a research note on Monday. Finally, National Securities increased their target price on shares of Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th.
Shares of NASDAQ:RKDA traded up $0.21 during trading on Wednesday, reaching $5.42. The stock had a trading volume of 172,571 shares, compared to its average volume of 1,262,908. The firm’s fifty day moving average is $4.76 and its 200 day moving average is $4.68. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.27 and a current ratio of 5.58. Arcadia Biosciences has a 52 week low of $1.82 and a 52 week high of $10.40. The stock has a market cap of $45.15 million, a price-to-earnings ratio of -1.01 and a beta of -2.98.
In related news, Director Kevin Comcowich bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average cost of $5.88 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at $117,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have purchased 32,200 shares of company stock worth $188,076. 3.30% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of RKDA. CVI Holdings LLC bought a new position in Arcadia Biosciences during the second quarter worth $414,000. Morgan Stanley boosted its stake in Arcadia Biosciences by 162,800.0% during the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after acquiring an additional 81,400 shares in the last quarter. Vanguard Group Inc. boosted its stake in Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after acquiring an additional 37,472 shares in the last quarter. Sabby Management LLC boosted its stake in Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Arcadia Biosciences during the third quarter worth $124,000. 8.03% of the stock is currently owned by institutional investors and hedge funds.
About Arcadia Biosciences
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Read More: What is the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.